home / stock / lxrx / lxrx news


LXRX News and Press, Lexicon Pharmaceuticals Inc. From 10/31/23

Stock Information

Company Name: Lexicon Pharmaceuticals Inc.
Stock Symbol: LXRX
Market: NASDAQ
Website: lexpharma.com

Menu

LXRX LXRX Quote LXRX Short LXRX News LXRX Articles LXRX Message Board
Get LXRX Alerts

News, Short Squeeze, Breakout and More Instantly...

LXRX - Lexicon Strengthens Management Team With Two New Executives

Matthew Cullen Joins as Vice President of Value and Access Lisa DeFrancesco Joins as Head of Investor Relations and Corporate Strategy THE WOODLANDS, Texas, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Matthew Cu...

LXRX - New Data Relating to Sotagliflozin to be Presented at the American Society of Nephrology (ASN) Kidney Week 2023 Annual Meeting

Presentations from four Lexicon-sponsored studies will highlight data supporting current and potential future use of sotagliflozin INPEFA ® (sotagliflozin) recently approved by FDA for treatment of heart failure THE WOODLANDS, Texas, Oct. 30, 2023 (G...

LXRX - Global Diabetes Care Market Size Expected To Reach $41.71 Billion By 2027

2023-10-25 08:45:23 ET Palm Beach, FL – October 25, 2023 – FinancialNewsMedia.com News Commentary – Recently, as the assorted global diabetes markets, such as drugs, devices and therapy continue to see an increased revenue yearly, so has the Diabetes Care Ma...

LXRX - Data From Two Studies Demonstrating Positive Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting

Abstracts for cost-effectiveness data and budget-impact model published in the Journal of Managed Care & Specialty Pharmacy (JMCP) INPEFA recently approved by FDA for treatment of heart failure THE WOODLANDS, Texas, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceu...

LXRX - Lexicon to present data on cost-effectiveness of Inpefa on Tuesday

2023-10-17 09:50:02 ET More on Lexicon Pharmaceuticals Looking Back In On Lexicon Pharmaceuticals Lexicon Pharmaceuticals Underway With Inpefa, But A Lot Of Hard Work Lexicon Rolls Out Inpefa For Heart Failure Amid Robust Competition Express Scripts to list L...

LXRX - 24/7 Market News Lunch Break 16 Oct 2023

2023-10-16 12:17:55 ET DENVER, Colo., Oct. 16, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Processa Pharmaceuticals Inc (NASDAQ: PCSA), Mereo BioPharma Group PLC (NASDAQ: MREO), Tempest Therape...

LXRX - 3 Top Penny Stocks to Buy According To Insiders In October

2023-10-16 10:35:20 ET Finding Penny Stocks through Insider Trading Activity Penny stocks, defined as stocks trading under $5 per share, offer traders huge upside potential but also carry significant risks. One strategy used by some investors to identify promising penny stocks i...

LXRX - LULU, CLSK and HUT are among pre market gainers

2023-10-16 08:30:08 ET PCTEL  ( NASDAQ: PCTI ) +48% . Essa Pharma  ( EPIX ) +32% . Almacenes Exito ( EXTO ) +32% . Ambrx Biopharma  ( AMAM ) +32% Provides Safety and Efficacy Data from Ongoing Phase 1/2 APEX-01 Trial of ARX5...

LXRX - Lexicon Pharmaceuticals says Debbane buys 1M shares in company

2023-10-13 09:34:50 ET More on Lexicon Pharmaceuticals Express Scripts to list Lexicon's Inpefa as preferred Medicare product Seeking Alpha’s Quant Rating on Lexicon Pharmaceuticals For further details see: Lexicon Pharmaceuticals says Debbane buys 1M shar...

LXRX - DG, GRPN and GFI are among pre market gainers

2023-10-13 08:12:01 ET EHang Holdings  ( EH ) +47% Successfully Obtains Type Certificate for EH216-S Passenger-Carrying UAV System Issued by Civil Aviation Administration of China. Comtech Telecommunications ( CMTL ) +15% . SEALSQ  ( LAES ) +13% ....

Previous 10 Next 10